Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

109.30
+0.95000.88%
Post-market: 109.300.00000.00%19:30 EDT
Volume:1.04M
Turnover:112.60M
Market Cap:9.09B
PE:-34.03
High:110.04
Open:106.52
Low:104.19
Close:108.35
52wk High:130.05
52wk Low:55.26
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.09
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.02
PE(LYR):-29.62

Loading ...

Kymera Therapeutics posts corporate presentation outlining oral immunology protein degrader pipeline

Reuters
·
Jun 09

Kymera Therapeutics, Sanofi dose first participant in Phase 1 trial of IRAK4 degrader KT-485

Reuters
·
Jun 09

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral Irak4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Eligible for up to $975 Mln in KT-485 Milestones

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Receive S $20 Mln Milestone Payment From Sanofi

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics: Buy Rating Reiterated as Analyst Maintains $110 Price Target on Emerging Protein Degrader Pipeline

TIPRANKS
·
Jun 09

Kymera Therapeutics COO Chadwick to Retire

Dow Jones
·
Jun 09

Kymera Therapeutics COO Resigns, Transition Plan Implemented

TIPRANKS
·
Jun 09

Kymera Therapeutics names Penny Carlson SVP, Development Operations

Reuters
·
Jun 09

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

GlobeNewswire
·
Jun 08

Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease

TIPRANKS
·
Jun 06

A Look At Kymera Therapeutics (KYMR) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Climb Bio (CLYM) and TransMedics Group (TMDX)

TIPRANKS
·
Jun 02

Top Kymera Executive Makes Major Move With Latest Stock Sale

TIPRANKS
·
May 28

Kymera Therapeutics COO Jeremy G. Chadwick disposes of common shares worth $1.64 million

Reuters
·
May 28

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire
·
May 27

Kymera presents Phase 1b data for KT-621 STAT6 degrader in atopic dermatitis

Reuters
·
May 15

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

THOMSON REUTERS
·
May 15

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

GlobeNewswire
·
May 15